The comprehensive continuous monitoring approach provided by Zio by iRhythm combines an easy-to-wear ambulatory biosensor patch and cloud-based technology to record and analyze up to 14 days of a patient’s heartbeats. The Zio diagnostic support services deliver clear, clinically actionable information to physicians in the form of a comprehensive report.
2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope
Syncope is the abrupt, temporary loss of consciousness, or fainting, which may be caused by cardiac arrhythmia. The "2017 ACC/AHA/HRS Guideline for the Evaluation and Management of Patients with Syncope," was published in the March editions of Circulation, the
It can be hard to diagnose the cause of syncope as symptoms often occur sporadically," said
The Medtech Innovation Briefing issued in the
It is vitally important, especially with the high number of emergency department visits and hospital admissions due to syncope, that diagnosis is made as quickly as possible thereby reducing unnecessary visits and admissions, said Trudie C. A. Lobban MBE, Founder and CEO of the international patient advocacy organizations
Patients find the Zio monitor easy to wear and non-intrusive as there are no wires. In fact it is just like wearing a large band-aid, and they can still shower or go to the gym, said Mrs. Lobban, whose organizations aim to reduce atrial fibrillation related strokes and ensure that arrhythmia patients are diagnosed and receive therapy sooner. Monitoring with Zio by iRhythm increases the chance of recording an event and therefore leads to a potentially quicker diagnosis.
There is a growing recognition of the advantages of the Zio monitoring system for patients compared to traditional cardiac monitoring, said
iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.
Investor Relations Contact
Lynn Pieper Lewisor Leigh Salvo(415) 937-5404 firstname.lastname@example.org Media Contact Aaron Murphy(415) 229-3331 email@example.com